These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 31266878)

  • 1. Host Carbon Dioxide Concentration Is an Independent Stress for Cryptococcus neoformans That Affects Virulence and Antifungal Susceptibility.
    Krysan DJ; Zhai B; Beattie SR; Misel KM; Wellington M; Lin X
    mBio; 2019 Jul; 10(4):. PubMed ID: 31266878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
    J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
    Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
    Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mismatch Repair of DNA Replication Errors Contributes to Microevolution in the Pathogenic Fungus
    Boyce KJ; Wang Y; Verma S; Shakya VPS; Xue C; Idnurm A
    mBio; 2017 May; 8(3):. PubMed ID: 28559486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
    Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
    Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid Flippase Subunit Cdc50 Mediates Drug Resistance and Virulence in Cryptococcus neoformans.
    Huang W; Liao G; Baker GM; Wang Y; Lau R; Paderu P; Perlin DS; Xue C
    mBio; 2016 May; 7(3):. PubMed ID: 27165800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.
    Bastos RW; Carneiro HCS; Oliveira LVN; Rocha KM; Freitas GJC; Costa MC; Magalhães TFF; Carvalho VSD; Rocha CE; Ferreira GF; Paixão TA; Moyrand F; Janbon G; Santos DA
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109169
    [No Abstract]   [Full Text] [Related]  

  • 9. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
    Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of capsule size on the in vitro activity of antifungal agents against clinical Cryptococcus neoformans var. grubii strains.
    Vitale RG; Pascuccelli V; Afeltra J
    J Med Microbiol; 2012 Mar; 61(Pt 3):384-388. PubMed ID: 22074850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
    Liaw SJ; Wu HC; Hsueh PR
    Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic diversity and antifungal susceptibility of environmental isolates of Cryptococcus neoformans from the Yangtze River Delta region of East China.
    Chen M; Wang Y; Li Y; Hong N; Zhu X; Pan W; Liao W; Xu J; Du J; Chen J
    Med Mycol; 2021 Jul; 59(7):653-663. PubMed ID: 33269400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.
    Sionov E; Chang YC; Garraffo HM; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2804-15. PubMed ID: 19414582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A unique chromosomal rearrangement in the Cryptococcus neoformans var. grubii type strain enhances key phenotypes associated with virulence.
    Morrow CA; Lee IR; Chow EW; Ormerod KL; Goldinger A; Byrnes EJ; Nielsen K; Heitman J; Schirra HJ; Fraser JA
    mBio; 2012; 3(2):. PubMed ID: 22375073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal Susceptibility of Clinical Isolates and Artificially Produced Multi-azole-resistant Strains of Cryptococcus neoformans (formerly: Cryptococcus grubii) to Ravuconazole.
    Kano R; Sugita T; Kamata H
    Med Mycol J; 2020; 61(1):11-13. PubMed ID: 32115444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil.
    Herkert PF; Meis JF; Lucca de Oliveira Salvador G; Rodrigues Gomes R; Aparecida Vicente V; Dominguez Muro M; Lameira Pinheiro R; Lopes Colombo A; Vargas Schwarzbold A; Sakuma de Oliveira C; Simão Ferreira M; Queiroz-Telles F; Hagen F
    J Med Microbiol; 2018 Apr; 67(4):560-569. PubMed ID: 29461182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virulence and antifungal susceptibility of environmental and clinical isolates of Cryptococcus neoformans from Puerto Rico.
    Fromtling RA; Abruzzo GK; Ruiz A
    Mycopathologia; 1989 Jun; 106(3):163-6. PubMed ID: 2682249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic diversity and antifungal susceptibility of Cryptococcus neoformans isolates from paediatric patients in China.
    Hong N; Chen M; Xu N; Al-Hatmi AMS; Zhang C; Pan WH; Hagen F; Boekhout T; Xu J; Zou XB; Liao WQ
    Mycoses; 2019 Feb; 62(2):171-180. PubMed ID: 30341799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.